ReviewBiosensors2025
The Personal Glucose Meter as the Measurement Principle in Point-of-Care Applications.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Specific Binding Agents for the Molecular Recognition of Biotoxins: Recent Advances and Applications in Forensic Toxicology.Molecules (Basel, Switzerland) · 2026Review
- Combined Use of Microwave Sensing Technologies and Artificial Intelligence for Biomedical Monitoring and Imaging.Biosensors · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A personal glucose meter (PGM) is a medical device that measures blood glucose levels and can be found worldwide. Owing to their sensitivity, simplicity, portability, and low cost, PGMs stand as one of the most frequently utilized analytical methods. This work reviews the different applied methodologies for detecting analytes other than glucose employing a PGM and how it can be incorporated for point-of-care diagnosis needs. To visualize the variants, first, a classification is made according to the biorecognition elements used (aptamers, antibodies, etc.), and where the determination of different analytes is done through the glucose signal using different glucose-generating enzymes such as invertase or glucosidase. Transduction can also be based on the use of nanocarriers that generally encapsulate glucose, although it is also possible to find a combination of the two aforementioned strategies. The PGM can also be used for the direct detection of interfering substances of the biosensor, such as NADH or paracetamol. Lastly, we discuss how a PGM might have been implemented to detect COVID-19 and how it could be used on a massive scale for the point-of-care diagnosis of a pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.